Table 5b |
||||||||
|
Gastrointestinal adverse events reported in studies of arthritis patients (part 2) |
||||||||
|
Number of |
Incidence of events (%) |
|||||||
|
|
||||||||
|
Outcome/ comparisons |
Celecoxib daily dose |
Comparator and daily dose |
Trials |
Patients |
Celecoxib |
Comparator |
Relative riska (95% CI) |
NNTpb or NNHc (95% CI) |
|
|
||||||||
|
Abdominal pain |
||||||||
|
|
||||||||
|
Celecoxib v placebo |
Any |
Placebo |
19 |
9,919 |
3.6 |
2.9 |
1.2 (0.92–1.5) |
|
|
Celecoxib v paracetamol |
Any |
Paracetamol 4,000 mg |
2 |
1,056 |
0.9 |
2.0 |
0.45 (0.15–1.3) |
|
|
Celecoxib v rofecoxib |
Any |
Rofecoxib 25 mg |
5 |
2,671 |
2.7 |
4.2 |
0.64 (0.42–0.97)a |
67 (35–920)b |
|
Celecoxib (200/400) v NSAID |
200–400 mg |
NSAID to maximum daily |
19 |
22,615 |
5.3 |
7.8 |
0.75 (0.68–0.83)a |
41 (32–57)b |
|
Celecoxib (any dose) v NSAID |
Any |
NSAID to maximum daily |
20 |
31,711 |
6.6 |
10.0 |
0.76 (0.70–0.82)a |
29 (25–36)b |
|
Celecoxib (any dose) v any active |
Any |
Any active comparator |
26 |
35,302 |
6.2 |
9.2 |
0.75 (0.70–0.81)a |
33 (28–41)b |
|
|
||||||||
|
Dyspepsia |
||||||||
|
|
||||||||
|
Celecoxib v placebo |
Any |
Placebo |
19 |
9,919 |
6.9 |
4.8 |
1.30 (1.08–1.6)a |
46 (32–84)c |
|
Celecoxib v paracetamol |
Any |
Paracetamol 4,000 mg |
2 |
1,056 |
2.9 |
2.2 |
1.34 (0.63–2.9) |
|
|
Celecoxib v rofecoxib |
Any |
Rofecoxib 25 mg |
5 |
2,671 |
4.4 |
4.9 |
0.89 (0.63–1.3) |
|
|
Celecoxib (200/400) v NSAID |
200–400 mg |
NSAID to maximum daily |
19 |
22,615 |
5.7 |
7.3 |
0.79 (0.71–0.88)a |
61 (43–100)b |
|
Celecoxib (any dose) v NSAID |
Any |
NSAID to maximum daily |
20 |
31,711 |
8.1 |
10.7 |
0.84 (0.78–0.90)a |
39 (31–52)b |
|
Celecoxib (any dose) v any active |
Any |
Any active comparator |
26 |
35,302 |
7.8 |
9.9 |
0.85 (0.79–0.91)a |
48 (37–68)b |
|
|
||||||||
|
Diarrhoea |
||||||||
|
|
||||||||
|
Celecoxib v placebo |
Any |
Placebo |
17 |
9,510 |
5.1 |
3.5 |
1.45 (1.16–1.82)a |
53 (37–97)c |
|
Celecoxib v paracetamol |
Any |
Paracetamol 4,000 mg |
2 |
1,056 |
2.2 |
4.6 |
0.48 (0.24–0.95)a |
41 (22–450)b |
|
Celecoxib v rofecoxib |
Any |
Rofecoxib 25 mg |
5 |
2,671 |
4.1 |
4.4 |
0.93 (0.65–1.3) |
|
|
Celecoxib (200/400) v NSAID |
200–400 mg |
NSAID to maximum daily |
17 |
22,071 |
4.3 |
4.9 |
0.96 (0.85–1.1) |
|
|
Celecoxib (any dose) v NSAID |
Any |
NSAID to maximum daily |
18 |
31,167 |
5.8 |
6.9 |
0.96 (0.88–1.1) |
|
|
Celecoxib (any dose) v any active |
Any |
Any active comparator |
24 |
34,758 |
5.6 |
6.6 |
0.95 (0.87–1.03) |
|
|
|
||||||||
|
Clinical ulcers and bleeds |
||||||||
|
|
||||||||
|
Celecoxib v placebo |
Any |
Placebo |
16 |
9,321 |
0.03 |
0.05 |
3 events |
|
|
Celecoxib v paracetamol |
Any |
Paracetamol 4,000 mg |
2 |
1,056 |
0.0 |
0.0 |
0 events |
|
|
Celecoxib v rofecoxib |
Any |
Rofecoxib 25 mg |
3 |
897 |
0.3 |
0.0 |
1 event |
|
|
Celecoxib (200/400) v NSAID |
200–400 mg |
NSAID to maximum daily |
17 |
22,075 |
0.2 |
0.6 |
0.35 (0.22–0.56)a |
250 (170–450)b |
|
Celecoxib (any dose) v NSAID |
Any |
NSAID to maximum daily |
18 |
31,171 |
0.4 |
0.9 |
0.61 (0.46–0.81)a |
200 (140–320)b |
|
Celecoxib (any dose) v any active |
Any |
Any active comparator |
22 |
32,508 |
0.4 |
0.8 |
0.61 (0.46–0.81)a |
210 (150–350)b |
|
|
||||||||
|
aRelative risk: bold indicates statistically significant difference. bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug. |
||||||||
|
Moore et al. Arthritis Research & Therapy 2005 7:R644 doi:10.1186/ar1704 |
||||||||